BIOATLA INC (BCAB:NASDAQ)
$3.91 0.22 (5.9621%)
Analysed BIOATLA INC (BCAB:NASDAQ) News Sources
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
07-11-2025
yahoo.com
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
13-11-2025
yahoo.com
BioAtla (BCAB) Q3 2025 Earnings Call Transcript
13-11-2025
fool.com
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
14-11-2025
yahoo.com
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
21-11-2025
yahoo.com
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
31-12-2025
yahoo.com
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
02-03-2026
yahoo.com
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
31-03-2026
yahoo.com
BioAtla Announces Share Consolidation
31-03-2026
yahoo.com
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18-05-2026
yahoo.com
What is the current price of BIOATLA INC (BCAB:NASDAQ)?
The current price of BIOATLA INC (BCAB:NASDAQ) is $3.91.
BIOATLA INC (BCAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOATLA INC (BCAB:NASDAQ) since the previous trading day is $0.22.
BIOATLA INC (BCAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOATLA INC (BCAB:NASDAQ) since the previous trading day is 5.9621%.
What is the most recent average sentiment score for BIOATLA INC (BCAB:NASDAQ)?
The most recent average sentiment score for BIOATLA INC (BCAB:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for BIOATLA INC (BCAB:NASDAQ)?
The most recent sentiment for BIOATLA INC (BCAB:NASDAQ) is .
SEC-8K** Filing Available For BIOATLA INC (BCAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.